Last seven days

All high-strength formulations of this drug are set to be discontinued in Australia, with the TGA implementing Serious Scarcity Substitution to support ongoing patient access

9 Oct 2026

Peter Mac spin-off starts life with $12M

The new radiopharma is backed by an investment syndicate led by 'Twiggy' Forrest's Tenmile with a mission to develop significant new medicines for hard-to-treat cancers

9 Oct 2026

Why this Awards comeback matters

Op-Ed: The return of Healthcare Marketing to Australia's prestigious Effie Awards means so much more than another gong for industry

9 Oct 2026

Who's left? Senior pharma leaders on the move

Three departures including one redundancy as leaders across industry move on, taking decades of company history with them

9 Oct 2026

So that's where he's gone: GM lands new job

After a significant stretch as one of industry's longest-serving ANZ Country Leaders this former GM has landed a new role

9 Oct 2026

Company cuts ties with reality TV star

DBG Health has severed ties with Sam Wood, who faces two domestic violence charges, after it acquired the reality TV star’s exercise and nutrition program

8 Oct 2026

Moderna enters five-year deal with CSIRO

mRNA powerhouse and Australia's national science agency launched a five-year strategic collaboration at Moderna's Melbourne plant this morning, with the first project unveiled

8 Oct 2026

What specialists really think of MSLs

While most specialists view MSLs positively almost a third describe their interactions as average or poor and almost one in three can't spot the difference between an MSL and Sales Rep

8 Oct 2026

Eczema drug back on PBS listing track

Following an extended back-and-forth with the PBAC, this pharma appears to be progressing its new treatment towards a PBS listing

8 Oct 2026

Smaller dose behind bigger profits?

Company catches up with how patients who are using this drug in the real world by kicking off a new trial and the upside could be a hike in profits

8 Oct 2026

'Totally unacceptable': Pharma slammed by UK watchdog

Slapped with the most serious Code of Conduct breach and reprimanded for a "significant failure" on transparency

7 Oct 2026

CSL raises $2B but it could come at a cost

The new loans carry an interest rate significantly higher than the ones being replaced

7 Oct 2026

TGA cracks down dishing $127K in fines

Australia's regulator has handed out a dozen fines for offences involving Eli Lilly's Mounjaro and Olumiant, along with a number of other drugs

7 Oct 2026

Archrivals face battle with a new enemy

This newcomer is set to disrupt a longtime rivalry between two Big Pharmas in a highly competitive space after stunning phase 3 results

7 Oct 2026

Drugs slated to exit Australia in 2027

Two well-known cancer drugs that historically generated around $50 million in annual sales each will be removed from the Australian market in the first half of 2027

7 Oct 2026

Why this therapy must move to an earlier line

Half of the cancer patients who received a one-shot therapy remain progression free after five years, follow-up results show

7 Oct 2026

Trial failure throws future of pharma into doubt

ASX-listed biopharma has gone into voluntary administration, seeking to preserve its intellectual property after a catastrophic Phase 3 trial failure

6 Oct 2026

Talent on the move: who's up, who's new, who's left

With only one quarter remaining of 2026, companies are already lining up their talent for next year with a flurry of promotions and new hires

6 Oct 2026

CSL makes $1.7B bet on first-in-class hopeful

Exclusive global partnership to co-develop and co-promote a potential game-changing therapy across a range of kidney and liver diseases

6 Oct 2026

Aussie first hits lucrative market

Roche is delivering the first innovative solution of its kind to Australian patients with the company already heading to the PBAC for reimbursement

6 Oct 2026

Friendly reminder